# NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

> **NCT02347839** · PHASE2 · WITHDRAWN · sponsor: **Sun Yat-sen University**

## Conditions studied

- Lung Cancer

## Interventions

- **PROCEDURE:** Gefitinib-surgery-gefitinib

## Key facts

- **NCT ID:** NCT02347839
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347839, "NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02347839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*